|
|
Post by lorcan458 on Feb 3, 2016 21:16:09 GMT -5
That would be just like Google geeks to use the HTML in page anchor location tag # with the double meaning in Twitter usage. I got unlucky with the forum having a page break without quoting you and I'm not sure how many of us know HTML. Here's what you posted: twitter.com/ReceptorLife/ #life www.gv.com/portfolio/#lifeAnd what I mean is the way to make a link scroll to a specific part of a page in HTML is to use a tag with an anchor name like #Life. The format for Twitter uses the same pound sign for a different purpose, so if #Life = #Life, Mannkind longs are eventually going to be very happy. |
|
|
|
Post by charleyd on Feb 3, 2016 21:20:12 GMT -5
I realize this is speculation, but here's my thinking: 1. Google partnered with Sanofi specifically for innovative diabetes treatment during the time that Sanofi had 65% of Afrezza. 2. There is no other innovative diabetes treatment in Sanofi's portfolio. 3. Google stated they are interested in the "Sanofi inhaler."4. As soon as it became apparent that insurance companies are going to force Afrezza to be priced on par with injectable insulin, Sanofi no longer found it profitable to take the expense and risk of Afrezza priced on par with injectables when it only gets 65% of the profits and their own injectable marketshare would decrease, from which they get 100% profit. 5. At that time, RLS poached a lead scientist from Mannkind. 6. Google reorganized under the umbrella of Alphabet and spun off Verily. Matt just said RLS was recently renamed. Google was recently renamed. When did Google state they are interested in the "Sanofi inhaler"? It is not in the press release announcing the collaboration: www.news.sanofi.us/2015-08-31-Sanofi-to-Collaborate-with-Google-Life-Sciences-to-Improve-Diabetes-Health-OutcomesWhat is said is the following: "About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including blood glucose monitoring systems. Sanofi markets injectable, inhaled and oral medications for people with type 1 or type 2 diabetes." |
|
|
|
Post by lorcan458 on Feb 3, 2016 21:24:03 GMT -5
Here: www.npr.org/sections/health-shots/2015/09/06/437570402/why-google-is-going-all-in-on-diabetesThe inhaler gets first billing in the sentence describing Sanofi. Why did the reporter think the inhaler was the only product to mention by name after interviewing the Google Life Scientist. Could it be that Google scientist was interested in the ONLY innovative diabetes product that Sanofi had in it's portfolio? Google Life Sciences earlier this week announced a partnership with Sanofi, maker of an insulin inhaler and a slew of other products for people with diabetes. |
|
|
|
Post by charleyd on Feb 3, 2016 21:31:57 GMT -5
I realize this is speculation, but here's my thinking: 1. Google partnered with Sanofi specifically for innovative diabetes treatment during the time that Sanofi had 65% of Afrezza. 2. There is no other innovative diabetes treatment in Sanofi's portfolio. 3. Google stated they are interested in the "Sanofi inhaler."4. As soon as it became apparent that insurance companies are going to force Afrezza to be priced on par with injectable insulin, Sanofi no longer found it profitable to take the expense and risk of Afrezza priced on par with injectables when it only gets 65% of the profits and their own injectable marketshare would decrease, from which they get 100% profit. 5. At that time, RLS poached a lead scientist from Mannkind. 6. Google reorganized under the umbrella of Alphabet and spun off Verily. Matt just said RLS was recently renamed. Google was recently renamed. When did Google state they are interested in the "Sanofi inhaler"? It is not in the press release announcing the collaboration: www.news.sanofi.us/2015-08-31-Sanofi-to-Collaborate-with-Google-Life-Sciences-to-Improve-Diabetes-Health-OutcomesWhat is said is the following: "About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including blood glucose monitoring systems. Sanofi markets injectable, inhaled and oral medications for people with type 1 or type 2 diabetes."This article gets a little closer, but still does not say that Google is "interested in the Sanofi Inhaler." It says: " Google Life Sciences earlier this week announced a partnership with Sanofi, maker of an insulin inhaler and a slew of other products for people with diabetes. Google is also working with Johnson & Johnson on surgical robots, Biogen on potential treatments for multiple sclerosis and Novartis and Dexcom on diabetes-related projects." However, these are the words of the article author, not Google. |
|
|
|
Post by charleyd on Feb 3, 2016 21:36:06 GMT -5
Thanks. Just saw this one myself, and contemporaneously replied to my own post. I guess it can possibly be inferred that the reporter mentions the "Sanofi inhaler" based upon her interview with the Google Life Sciences spokesperson that is interviewed. In Mythbuster parlance, I think this makes your assertion "plausible." |
|
|
|
Post by lorcan458 on Feb 3, 2016 21:41:05 GMT -5
I was editing just as you posted below me. I am trying not to embed quote upon quote. It makes the thread longer and repetitive. See my explanation above and I don't know about the rest of you, but I prefer to quote only the minimum amount needed to avoid confusion.
For me, the bottom line is why did Google choose Sanofi as a diabetes partner? What Google-style innovation did Sanofi have other than Afrezza? What Google-level innovative diabetes treatment is there from ANYONE other than Afrezza. Long or short, everyone has to admit that currently Afrezza is the one and only fundamentally innovative insulin on the planet.
|
|
|
|
Post by harryx1 on Feb 3, 2016 22:17:58 GMT -5
someone here's gonna figure out who RLS was beforehand. i'm betting on harry! Actually I find it more fun to watch the shorts having no clue who they are & what capabilities/potential they might have.  ?? |
|
|
|
Post by longinvstr on Feb 3, 2016 22:30:38 GMT -5
someone here's gonna figure out who RLS was beforehand. i'm betting on harry! Actually I find it more fun to watch the shorts having no clue who they are & what capabilities/potential they might have. ?? Right, and for all their advantages, the "institutions" are obviously diseased by the mystery as evidenced by the JPM query Like the rest of us, they can enjoy the life of a mushroom for awhile |
|
|
|
Post by patten1962 on Feb 3, 2016 22:37:49 GMT -5
My question is if Mannkind was going to file bankruptcy why would they go through the trouble of setting up and getting a deal with Receptor Life Sciences? Why go through all this trouble. Does not make sense to me. I truly believe something good is coming. If I'm wrong I lose a lot of money.
|
|
|
|
Post by boomboom on Feb 3, 2016 22:52:58 GMT -5
|
|
|
|
Post by hawaiiguy42 on Feb 4, 2016 0:25:20 GMT -5
someone here's gonna figure out who RLS was beforehand. i'm betting on harry! Actually I find it more fun to watch the shorts having no clue who they are & what capabilities/potential they might have. ?? You are on the money Harry, I like to call it the "Element of Surprise." |
|
|
|
Post by lorcan458 on Feb 4, 2016 0:29:06 GMT -5
These are shells, just placeholders, as evidenced by the address being a residential house and the VP's being lawyers from the Lane Powell law firm. RLS has enough money to go after 3 drugs on the initial deal. If it's not Alphabet, it's someone else who values privacy while the chess pieces are being arranged. |
|
|
|
Post by theloozzz on Feb 4, 2016 7:17:18 GMT -5
|
|
|
|
Post by bthomas55ep on Feb 4, 2016 7:32:40 GMT -5
Thanks. Just saw this one myself, and contemporaneously replied to my own post. I guess it can possibly be inferred that the reporter mentions the "Sanofi inhaler" based upon her interview with the Google Life Sciences spokesperson that is interviewed. In Mythbuster parlance, I think this makes your assertion "plausible." I'm not quite sure how the dots connect. RLS is using T/S to proof of concept a compound they own - who knows what indication. Afrezza is the inhaled insulin and it currently has nothing to do with the RLS deal. If RLS was Google Life Sciences hoping to build a Diabetes portal, wouldn't Afrezza be the target? |
|
|
|
Post by lorcan458 on Feb 4, 2016 7:52:09 GMT -5
I'm not quite sure how the dots connect. RLS is using T/S to proof of concept a compound they own - who knows what indication. Afrezza is the inhaled insulin and it currently has nothing to do with the RLS deal. If RLS was Google Life Sciences hoping to build a Diabetes portal, wouldn't Afrezza be the target? Not necessarily in the initial press release while Google and Mannkind are still is partnered with Sanofi and Sanofi still maintains the rights to Afrezza. Plus, they may be playing hardball with Al, if his price is too high. Al and the longs: Look at the medical results on Twitter. $40 a share and 10% perpetual royalites. Big Pharma and Google: How do I sell that number to my shareholders? Huge risk. Huge money. You might be more reasonable on the price in a few months when your cash reserves are depleted. We can wait. |
|
